This report provides exclusive insights into the COVID-19 impact on the Radiopharmaceuticals Market. The detailed analysis provides information about the impact of the outbreak on the demand and supply conditions, trends and forecasts of the Radiopharmaceuticals Market. Moreover, the impact analysis covers the study of the COVID-19 on the supply chain of Radiopharmaceuticals Market. The sectoral impact shall provide insights into both short term and long term effects of the pandemic on the related and support industries.
A recent report published by Infinium Global Research on
radiopharmaceuticals market provides in-depth analysis of segments and
sub-segments in the global as well as regional radiopharmaceuticals market. The
study also highlights the impact of drivers, restraints, and macro indicators
on the global and regional radiopharmaceuticals market over the short term as
well as long term. The report is a comprehensive presentation of trends,
forecast and dollar values of the global radiopharmaceuticals market. According to
the report, the global radiopharmaceuticals market is projected to grow at a
CAGR of 8.5% over the forecast period of 2019-2025.
Radiopharmaceuticals used in molecular and nuclear imaging serve a
vital purpose inpatient care. Radiopharmaceuticals are unique medicinal
formulations encompassing radioisotopes which are used in major clinical areas
for diagnosis and therapy. Radioisotopes are used as nuclear medicines which
emit alpha and beta emission rays for treating diseases. Radiopharmaceutical
products are used for the treatment of diseases such as cancer, cardiovascular
heart disease, neurology, and bone fracture detection.
The rapidly expanding rates of cancer and cardiovascular diseases
are the primary driving factor for the growth of the radiopharmaceuticals
market. In addition, the cancer rates could further increase by 50% to 15
million new cases in the year 2020, according to the World Cancer Report.
Growth in cancer diagnostics and treatments have ignited the preference of
doctors towards the utilization of radiopharmaceuticals. Radiopharmaceuticals
like F-18, samarium, and technetium, which contribute more than 75% to the
PET-analysis showcase, are utilized as a part of imaging to analyze cancer and
cardiac diseases. With the expanding frequency of cancer and cardiovascular
infections, the interest for radiopharmaceuticals will likewise increase.
Furthermore, public-private partnerships are emerging for modernization of the
healthcare infrastructure owing to the high cost of nuclear medicine devices
and budget constraints. This factor is also aiding the adoption of
radiopharmaceuticals for several treatments. However, comparatively short life
of radiopharmaceuticals coupled with high cost hampers the growth of the
market. Moreover, the growing focus on targeted therapies and an increasing number
of potential radioisotopes in the pipeline creates fruitful opportunities for
the market players.
Among the regions, North America is expected to hold the largest
share in the global radiopharmaceuticals market. The U.S. radiopharmaceuticals
market is estimated to be the largest market among the North American
countries. The installation of new cyclotrons, an increase in the incidence of
cancer and heart patients, and well-defined reimbursement policies from public
and private health insurance firms fuel the growth of the radiopharmaceuticals
market in the U.S. market. In addition, according to the World Nuclear
Association, U.S. based Coqui Pharmaceuticals signed a contract with
Argentinian nuclear engineering company INVAP to build an open-pool reactor
similar to Australia’s Opal reactor in order to have better Mo-99 production facility
at Alachua County, Florida. Europe is anticipated to hold the second-largest
share owing to the growing prevalence of cancer and increasing reimbursement
The report on global radiopharmaceuticals market covers segments such
as radioisotopes and end-users. On the basis of radioisotopes, the sub-markets
include technetium-99, thallium-201, gallium-67, iodine-123, flourine-18,
rubidium-82, yttrium-90, lutetium-177, and other radioisotopes. On the basis of
end-users, the sub-markets include hospitals, ambulatory surgical centers,
diagnostic centers, and research centers.
The report provides profiles of the companies in the market such
as GE Healthcare, Cardinal Health, Inc., Mallinckrodt Pharmaceuticals, Lantheus
Medical Imaging, Inc., Bayer AG, Advanced Accelerator Applications S.A., Bracco
Imaging S.p.A., Eczacibasi Monrol Nuclear Products Co., Nordion Inc., and
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of
radiopharmaceuticals market. Moreover, the study highlights current market
trends and provides forecast from 2019-2025. We also have highlighted future
trends in the market that will affect the demand during the forecast period.
Moreover, the competitive analysis given in each regional market brings an
insight into the market share of the leading players.